191 related articles for article (PubMed ID: 22633552)
21. Dose escalation with 3D-CRT in prostate cancer: French study of dose escalation with conformal 3D radiotherapy in prostate cancer-preliminary results.
Bey P; Carrie C; Beckendorf V; Ginestet C; Aletti P; Madelis G; Luporsi E; Pommier P; Cowen D; Gonzague-Casabianca L; Simonian-Sauve M; Maingon P; Naudy S; Lagrange J; Marcie S
Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):513-7. PubMed ID: 10974470
[TBL] [Abstract][Full Text] [Related]
22. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
23. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
[TBL] [Abstract][Full Text] [Related]
24. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
Stock RG; Stone NN
Brachytherapy; 2002; 1(1):2-10. PubMed ID: 15062181
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
[TBL] [Abstract][Full Text] [Related]
26. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer.
Kupelian PA; Reddy CA; Carlson TP; Altsman KA; Willoughby TR
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):904-12. PubMed ID: 12095556
[TBL] [Abstract][Full Text] [Related]
27. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II.
Michalski JM; Winter K; Purdy JA; Wilder RB; Perez CA; Roach M; Parliament MB; Pollack A; Markoe AM; Harms W; Sandler HM; Cox JD
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):192-8. PubMed ID: 12694838
[TBL] [Abstract][Full Text] [Related]
28. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study.
Michalski JM; Bae K; Roach M; Markoe AM; Sandler HM; Ryu J; Parliament MB; Straube W; Valicenti RK; Cox JD
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):14-22. PubMed ID: 19577865
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant LHRH analog plus estramustine phosphate combined with three-dimensional conformal radiotherapy for intermediate- to high-risk prostate cancer: a randomized study.
Hirano D; Nagane Y; Satoh K; Mochida J; Sugimoto S; Ichinose T; Takahashi S; Maebayashi T; Saitoh T
Int Urol Nephrol; 2010 Mar; 42(1):81-8. PubMed ID: 19449118
[TBL] [Abstract][Full Text] [Related]
30. Image guided dose escalated prostate radiotherapy: still room to improve.
Martin JM; Bayley A; Bristow R; Chung P; Gospodarowicz M; Menard C; Milosevic M; Rosewall T; Warde PR; Catton CN
Radiat Oncol; 2009 Nov; 4():50. PubMed ID: 19887007
[TBL] [Abstract][Full Text] [Related]
31. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
[TBL] [Abstract][Full Text] [Related]
32. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
[TBL] [Abstract][Full Text] [Related]
33. Dose selection for prostate cancer patients based on dose comparison and dose response studies.
Hanks GE; Hanlon AL; Pinover WH; Horwitz EM; Price RA; Schultheiss T
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):823-32. PubMed ID: 10705002
[TBL] [Abstract][Full Text] [Related]
34. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
[TBL] [Abstract][Full Text] [Related]
35. Optimal local control and tolerability of three-dimensional conformal radiation therapy in prostate cancer: a single institutional experience of dose escalation in 125 patients.
Ferrera G; Caminiti G; Grillo A; Alongi F; Evangelista G; Greco E; Cucchiara T; Bono M; Mortellaro G; Cirrincione A; Dalia F; Iacoviello G; Caputo V; Midiri M; Sciumè F
Tumori; 2013; 99(6):676-81. PubMed ID: 24503790
[TBL] [Abstract][Full Text] [Related]
36. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
[TBL] [Abstract][Full Text] [Related]
37. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
38. Comparing morbidity and cancer control after 3D-conformal (70/74 Gy) and intensity modulated radiotherapy (78/82 Gy) for prostate cancer.
Dolezel M; Odrazka K; Zouhar M; Vaculikova M; Sefrova J; Jansa J; Paluska P; Kohlova T; Vanasek J; Kovarik J
Strahlenther Onkol; 2015 Apr; 191(4):338-46. PubMed ID: 25589224
[TBL] [Abstract][Full Text] [Related]
39. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.
Zelefsky MJ; Leibel SA; Gaudin PB; Kutcher GJ; Fleshner NE; Venkatramen ES; Reuter VE; Fair WR; Ling CC; Fuks Z
Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):491-500. PubMed ID: 9635694
[TBL] [Abstract][Full Text] [Related]
40. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.
Zietman AL; DeSilvio ML; Slater JD; Rossi CJ; Miller DW; Adams JA; Shipley WU
JAMA; 2005 Sep; 294(10):1233-9. PubMed ID: 16160131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
